Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome
1. Among patients with primary Sjögren syndrome, therapy with low-dose interleukin 2 significantly improved outcomes as determined by the European ...
1. Among patients with primary Sjögren syndrome, therapy with low-dose interleukin 2 significantly improved outcomes as determined by the European ...
1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. ...
1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. ...
Originally published by Harvard Health. What Is It? Sjögren’s (pronounced "show grins") syndrome is a chronic (or lifelong) condition that ...
1. After 24 weeks of treatment, hydroxychloroquine was no more effective than placebo in improving scores for dryness, pain, and ...
Image: PD 1. 66% of patients with Sjögren’s Syndrome (SS) in this study had autoantibodies detected in the serum prior ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.